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Themechanism of lipoprotein lipase (LPL) transport frommuscle and fat cells to the luminal (apical) surface of
capillaries, where it hydrolyses lipoprotein triglycerides, has remained undefined. In this issue, Davies et al.
(2010) report that GPIHBP1 is required for LPL transcytosis from the basolateral to apical capillary endothelial
surface.From a health perspective, the two most
important lipid components on lipopro-
teins are cholesterol and triglycerides,
and their elevations in the plasma have
been associated with coronary artery
disease. All classes of lipoprotein parti-
cles transport cholesterol, but triglycer-
ides are particularly abundant in very low
density lipoproteins (secreted by the liver)
and in chylomicrons (secreted by the
intestine). These triglyceride-rich lipopro-
teins (TGRLs) are substrates of the
enzyme lipoprotein lipase (LPL) on the
apical (luminal) surface of capillary endo-
thelia of muscle or fat tissue; however,
the source of LPL is not the endothelial
cells, but the underlying myocytes or
adipocytes. How secreted LPL traverses
the endothelium has been a long-stand-
ing mystery. For example, a previous
model for the transcytosis of LPL across
endothelial cells implicated the VLDL
receptor (Obunike et al., 2001), but the
physiological relevance of this mecha-
nism was undermined by the lack of hy-
pertriglyceridemia in mice deficient in the
VLDL receptor (Frykman et al., 1995). Gly-
cosylphosphatidylinositol-anchored high-
density lipoprotein-binding protein 1
(GPIHBP1) became a plausible contender
as a transport factor when it was shown to
be a platform on which TGRLs are pre-
sented to LPL on the apical surface of
capillary endothelial cells (Beigneux
et al., 2007).
Davies et al. (2010) beautifully weave
data from in vitro and in vivo approaches
to make a strong case for GPIHBP10s
role as a shuttle by which LPL travels
from the interstitial space between the
parenchymal cells of adipose or muscle
tissue and endothelial cells to the luminal
surface of the capillary. Besides filling a
large gap in LPL biology, the results pro-
vide mechanistic information to explainwhy humans with mutant GPIHBP1 have
hypertriglyceridemia (Beigneux et al.,
2009) even though they have adequate
tissue stores of LPL—simply put, the
enzyme never reaches the apical surfaces
of the endothelial cells, and therefore,
the hydrolysis of triglycerides and their
subsequent clearance from plasma do
not occur.
An important early clue was the finding
of GPIHBP1 and LPL colocalized on
both the basolateral and apical surfaces
of capillary endothelial cells. Using an
impressive battery of tools, most notably
an antibody (11A12) that in vitro under-
goes transport across endothelial cells
in a GPIHBP1-dependent manner, the
authors showed that LPL was transported
with GPIHBP1 across endothelial cells
from the basolateral to the apical surface.
Notably, this shuttle function depended
on the ability of GPIHBP1 to bind LPL, a
finding supported by the severe hypertri-
glyceridemia in humans with mutations
in GPIHBP1 that impair LPL binding
(Beigneux et al., 2009; Franssen et al.,
2010; Olivecrona et al., 2010). To extend
the cell culture studies and demonstrate
GPIHBP1 transporter activity in vivo, the
authors injected the 11A12 antibody into
the quadriceps muscle of wild-type or
GPIHBP1-deficient mice. Only in the
wild-type mice was there evidence that
the antibody had been taken up by endo-
thelial cells and transported into the lumen
of capillaries. Taken with the data in vitro,
these results strongly support a critical
role for GPIHBP1 in the transcytosis of
LPL across capillary endothelia (Figure 1).
A number of interesting questions come
to mind. For example, is the transport
machinery directed exclusively toward
GPIHBP1, with LPL as a passive fellow
traveler, or does LPL contribute to the
specificity of its shuttling through interac-Cell Metabotions with additional proteins? The
authors speculate that caveolae may be
involved in LPL transport, given their
association with GPI-anchored proteins,
as well as their abundance in endothelial
cells and known participation in transcy-
tosis (Frank et al., 2009). Undoubtedly
there will be other candidate transport
factors to consider. One class of mole-
cules may be heparan sulfate proteogly-
cans, given that they bind LPL and
undergo caveolar-associated recycling
(reviewed in Williams, 2009).
Other questions are more ‘‘transla-
tional’’ in nature. As noted above, there
are reports of patients with severe hyper-
triglyceridemia who have mutations in
GPIHBP1. While there are other genetic
causes of hypertriglyceridemia, such as
mutations of LPL or of its activator apo-
protein CII, it is currently unknown how
many other unexplained familial hypertri-
glyceridemias can be attributed to loss
of GPIHBP1 function. Another intriguing
possibility is that GPIHBP1 could be
a regulator of energy traffic—if the abun-
dance of GPIHBP1 is regulated in tissues
expressing LPL, then GPIHBP1 could be
a major factor in determining the amount
of fat calories directed to energy produc-
tion or storage, which would have an
important influence on insulin sensitivity
and glucose tolerance.
In summary, an important advance in
our knowledge about TGRL metabolism
has been made by Davies et al. (2010).
There are now convergent data from
cell-culture studies, mouse models, and
human genetics to build a strong case
for GPIHBP1 as LPL’s ticket to ride across
the capillary endothelium in tissues where
TGs are hydrolyzed. Further investigation
of GPIHBP1 is likely to illuminate the
fundamental cell biology of transcytosis,
the molecular regulation of plasmalism 12, July 7, 2010 ª2010 Elsevier Inc. 1
Figure 1. A Schematic View of LPL Transport by GPIHBP1
GPIHBP1 is expressed on both the apical and basolateral surfaces of endothelial cells of capillaries in muscle and fat. Lipoprotein lipase molecules (LPL; yellow
shapes) are secreted from the underlying parenchymal cells into the subendothelial space. After binding of LPL to a specific domain of GPIHBP1 (in red), the
GPIHBP1-LPL complex is then transported from the basolateral surface across the endothelial cell, arriving at the apical surface.
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Previewstriglyceride levels, and the partitioning
of energy among tissues. The role of
GPIHBP1 in regulating plasma triglyc-
eride levels already link it to hyperlipid-
emia and cardiovascular disease risk,
and future studies in energy partitioning
may also connect it to those two other
scourges of the developed world, obesity
and diabetes.
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